This session will explore the history of DMT leading up to IRTs, with a focus on Mavenclad. Safety considerations include managed lymphopenia, infection monitoring, and tailored patient selection criteria. The discussion emphasizes early IRT initiation to optimize long-term disease control in eligible patients.

This session explores Mavenclad unique mode of action as an IRT, selectively targeting lymphocytes to disrupt MS disease activity. Its intermittent dosing provides sustained efficacy by
allowing immune repopulation while maintaining long-term disease control. The approach minimizes continuous immunosuppression, offering durable benefits with a limited treatment course.

We will demonstrate Mavenclad’s real-world effectiveness, showing better results than other oral platform DMTs in relapse reduction and treatment persistence. Early use is linked to sustained disease control and improved patient outcomes. The session explores its practical clinical application and safety advantages

This panel discussion explores the benefits of Mavenclad as an IRT in early relapsing MS. Experts will highlight its unique mechanism, durable efficacy from real-world data, and practical advantages like short-course oral dosing. Key topics include safety comparisons with anti-CD20 therapies and lifestyle benefits for patients

In this session, the speaker will present two Interactive clinical cases with the HCPs demonstrating the application of Mavenclad in MS management. One case features a treatment-naive patient starting Mavenclad, while the other focuses on a patient who was switched to Mavenclad after inadequate response to previous therapies. The discussion will emphasize the clinical decision-making process, treatment outcomes, and outcomes seen from both cases.

This session will focus on the strategic approach to sequencing DMTs with a focus on switching to Mavenclad. It will outline the criteria for identifying suitable candidates for the switch, addressing timing and patient considerations, as well as the clinical benefits of early intervention with Mavenclad. It will provide practical guidance on optimizing treatment pathways to enhance patient outcomes.

This panel discussion focuses on individualized MS care, exploring how Mavenclad fits into tailored treatment strategies. Experts will address patient selection, switching protocols from anti-CD20 therapies, and optimal monitoring during washout periods from various DMTs. The session will provide practical insights for optimizing outcomes with Mavenclad in diverse clinical scenarios.

This session will focus on the use of Mavenclad and Rebif in special populations, particularly the elderly and women planning for pregnancy. A fertility specialist will provide insights on emotional and mental health in fertility for both partners and addressing anxieties, fears, and the need for coping mechanisms and support networks. The session will address the challenges for optimizing therapy while supporting reproductive health and overall well-being in patients with MS.